Exonate Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $1.9M

  • Investors
  • 16

Exonate General Information

Description

Developer of biopharmaceutical drug designed to improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss. The company offers program molecules, for wet Age-Related Macular Degeneration (wet AMD), which act via a novel mechanism of action to inhibit pathological blood vessels and reduce the formation of pathological vascular endothelial growth factor without inhibiting beneficial, non-pathological VEGF, thereby enabling doctors to focus on developing novel therapies for wet age-related macular degeneration.

Contact Information

Website
www.exonate.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • WTL Moorfield Road, Duxford
  • Cambridgeshire
  • Cambridge CB22 4PS
  • England, United Kingdom
+44 01223 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exonate Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) 03-Jan-2019 $1.9M 00.000 Completed Generating Revenue
6. Later Stage VC 12-Sep-2018 00.000 00.000 00.000 Completed Clinical Trials - Phase 1
5. Grant 06-Feb-2017 00.000 00.000 Completed Clinical Trials - Phase 1
4. Early Stage VC 01-Dec-2016 00.00 00.000 00.000 Completed Clinical Trials - Phase 1
3. Early Stage VC 05-Oct-2015 00.000 00.000 00.000 Completed Clinical Trials - Phase 1
2. Seed Round 01-Mar-2014 $651K $651K 00.000 Completed Clinical Trials - Phase 1
1. Spin-Off 01-Jan-2013 Completed Startup
To view Exonate’s complete valuation and funding history, request access »

Exonate Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 14,141 $0.012877 $72.11 $72.11 1x $72.11 17.79%
Ordinary 7,860 $0.012877 $64.39 $64.39 1x $64.39 9.89%
To view Exonate’s complete cap table history, request access »

Exonate Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical drug designed to improve the treatment of patients with retinal vascular diseases and to
Drug Discovery
Cambridge, United Kingdom
18 As of 2024
00.000
00000000000 00.000

000000

e irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat n
0000 000000000
Oxford, United Kingdom
00 As of 0000
0000
0000000000 0000

000000

eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
London, United Kingdom
00 As of 0000
00000
00.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exonate Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxular Venture Capital-Backed Oxford, United Kingdom 00 0000 0000000000 0000
Gyroscope Formerly VC-backed London, United Kingdom 00 00000 000000&0 00000
TearSolutions Venture Capital-Backed Charlottesville, VA 00 0000 0000000000 0 0000
Allegro Ophthalmics Venture Capital-Backed San Juan Capistrano, CA 0 000.00 0000000000 0 000.00
PulseSight Therapeutics Venture Capital-Backed Paris, France 00 000.00 00000000000 000.00
You’re viewing 5 of 27 competitors. Get the full list »

Exonate Patents

Exonate Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021309894-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Pending 14-Jul-2020 0000000000
GB-202010829-D0 Compounds for treatment of neovascular diseases Inactive 14-Jul-2020 0000000000
CA-3183466-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Pending 14-Jul-2020 0000000000
US-20220411412-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Active 14-Jul-2020 0000000000 0
EP-4182311-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Pending 14-Jul-2020 C07D405/14
To view Exonate’s complete patent history, request access »

Exonate Executive Team (5)

Name Title Board Seat
Loic Lhuillier Ph.D Chief Operating Officer
Christopher O'Connor Financial Controller
Catherine Beech MD Co-Founder & Board Member
Lucy Donaldson Ph.D Co-Founder
You’re viewing 4 of 5 executive team members. Get the full list »

Exonate Board Members (10)

Name Representing Role Since
Andrew Garland Ph.D Self Board Member 000 0000
Andrew Naylor Self Board Member 000 0000
Catherine Beech MD Exonate Co-Founder & Board Member 000 0000
Christopher Torrance Ph.D Self Board Member 000 0000
John Kurek Ph.D Uniseed Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Exonate Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exonate Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Stoic Venture Capital Venture Capital Minority 000 0000 000000 0
University of Bristol Endowment Limited Partner Minority 000 0000 000000 0
R42 Group Venture Capital Minority 000 0000 000000 0
Wellcome Trust Limited Partner 000 0000 000000 0
Martlet Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

Exonate FAQs

  • When was Exonate founded?

    Exonate was founded in 2013.

  • Who is the founder of Exonate?

    Catherine Beech MD, David Bates Ph.D, and Lucy Donaldson Ph.D are the founders of Exonate.

  • Where is Exonate headquartered?

    Exonate is headquartered in Cambridge, United Kingdom.

  • What is the size of Exonate?

    Exonate has 18 total employees.

  • What industry is Exonate in?

    Exonate’s primary industry is Drug Discovery.

  • Is Exonate a private or public company?

    Exonate is a Private company.

  • What is Exonate’s current revenue?

    The current revenue for Exonate is 00000.

  • How much funding has Exonate raised over time?

    Exonate has raised $7.74M.

  • Who are Exonate’s investors?

    Stoic Venture Capital, University of Bristol Endowment, R42 Group, Wellcome Trust, and Martlet Capital are 5 of 16 investors who have invested in Exonate.

  • Who are Exonate’s competitors?

    Oxular, Gyroscope, TearSolutions, Allegro Ophthalmics, and PulseSight Therapeutics are some of the 27 competitors of Exonate.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »